Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.5 USD | +1.57% | -0.23% | +50.08% |
03/05 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
02/05 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.08% | 2.33B | |
+20.15% | 44.96B | |
+1.24% | 42.65B | |
+46.23% | 41.85B | |
-4.27% | 29.04B | |
+11.63% | 26.08B | |
-21.15% | 19.03B | |
+4.73% | 12.75B | |
+27.30% | 12.06B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises